SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0028 4793 OR L773:1533 4406 srt2:(2020-2024)"

Sökning: L773:0028 4793 OR L773:1533 4406 > (2020-2024)

  • Resultat 51-60 av 117
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
51.
  •  
52.
  •  
53.
  •  
54.
  •  
55.
  •  
56.
  •  
57.
  •  
58.
  •  
59.
  •  
60.
  • Connolly, Stuart J., et al. (författare)
  • Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
  • 2024
  • Ingår i: New England Journal of Medicine. - 0028-4793. ; 390:19, s. 1745-1755
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied. Methods We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care. The primary end point was hemostatic efficacy, defined by expansion of the hematoma volume by 35% or less at 12 hours after baseline, an increase in the score on the National Institutes of Health Stroke Scale of less than 7 points (scores range from 0 to 42, with higher scores indicating worse neurologic deficit) at 12 hours, and no receipt of rescue therapy between 3 hours and 12 hours. Safety end points were thrombotic events and death. Results A total of 263 patients were assigned to receive andexanet, and 267 to receive usual care. Efficacy was assessed in an interim analysis that included 452 patients, and safety was analyzed in all 530 enrolled patients. Atrial fibrillation was the most common indication for factor Xa inhibitors. Of the patients receiving usual care, 85.5% received prothrombin complex concentrate. Hemostatic efficacy was achieved in 150 of 224 patients (67.0%) receiving andexanet and in 121 of 228 (53.1%) receiving usual care (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 4.6 to 22.2; P=0.003). The median reduction from baseline to the 1-to-2-hour nadir in anti-factor Xa activity was 94.5% with andexanet and 26.9% with usual care (P<0.001). Thrombotic events occurred in 27 of 263 patients (10.3%) receiving andexanet and in 15 of 267 (5.6%) receiving usual care (difference, 4.6 percentage points; 95% CI, 0.1 to 9.2; P=0.048); ischemic stroke occurred in 17 patients (6.5%) and 4 patients (1.5%), respectively. There were no appreciable differences between the groups in the score on the modified Rankin scale or in death within 30 days. Conclusions Among patients with intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better control of hematoma expansion than usual care but was associated with thrombotic events, including ischemic stroke. (Funded by Alexion AstraZeneca Rare Disease and others; ANNEXA-I ClinicalTrials.gov number, NCT03661528.).
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 51-60 av 117
Typ av publikation
tidskriftsartikel (116)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (92)
övrigt vetenskapligt/konstnärligt (25)
Författare/redaktör
Fasching, PA (4)
Stone, Gregg W. (4)
Mark, Daniel B. (4)
Schmid, P. (3)
Bergh, J (3)
Takahashi, M. (3)
visa fler...
O'Shaughnessy, J (3)
Harbeck, N (3)
Grubb, Anders (3)
Melander, Olle (3)
Cardoso, F (3)
Untch, M (3)
Alexander, Karen P. (3)
Held, Claes (3)
Xu, L. (2)
Tryfonidis, K (2)
Rydén, L. (2)
Hansson, Magnus (2)
Larsson, Anders (2)
Carrero, JJ (2)
Chew, Michelle (2)
Eriksson, M (2)
Ding, Y. (2)
Ponikowski, Piotr (2)
Linde, C (2)
Gold, MR (2)
Lind, Lars (2)
Eklund, M (2)
Kim, JS (2)
Ludvigsson, JF (2)
Ahn, JH (2)
Filippatos, Gerasimo ... (2)
Brenner, Hermann (2)
Andersson, Jonas (2)
Voors, Adriaan A. (2)
Andersen, J. (2)
Malekzadeh, Reza (2)
Sardh, E (2)
Atar, D (2)
Thålin, C (2)
James, Stefan, 1964- (2)
Linneberg, Allan (2)
Rossing, Peter (2)
Hillemanns, P (2)
Björk, Jonas (2)
Eggers, Kai M., 1962 ... (2)
Alegre-Díaz, Jesus (2)
Erglis, Andrejs (2)
Eichhorst, B (2)
James, Stefan (2)
visa färre...
Lärosäte
Karolinska Institutet (71)
Uppsala universitet (18)
Lunds universitet (18)
Göteborgs universitet (16)
Linköpings universitet (12)
Umeå universitet (10)
visa fler...
Örebro universitet (5)
Kungliga Tekniska Högskolan (2)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (117)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (61)
Teknik (2)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy